Immunomodulatory e ects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells
|
|
- Oswin Peters
- 6 years ago
- Views:
Transcription
1 FEMS Immunology and Medical Microbiology 38 (2003) 165^172 Immunomodulatory e ects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells Karen Manon Lammers a;, Patrizia Brigidi b, Beatrice Vitali b, Paolo Gionchetti a, Fernando Rizzello a, Elisabetta Caramelli c, Diego Matteuzzi b, Massimo Campieri a a Department of Internal Medicine and Gastroenterology, University of Bologna, Policlinic S. Orsola, Via Massarenti 9, Bologna, Italy b Department of Pharmaceutical Sciences, University of Bologna, Bologna, Italy c Department of Histology and General Embryology, University of Bologna, Bologna, Italy Received 27 February 2003; received in revised form 3 April 2003; accepted 10 April 2003 First published online 17 May 2003 Abstract A new therapeutic approach for inflammatory bowel diseases is based on the administration of probiotic bacteria. Prokaryotic DNA contains unmethylated CpG motifs which can activate immune responses, but it is unknown whether bacterial DNA is involved in the beneficial effects obtained by probiotic treatment. Peripheral blood mononuclear cells (PBMC) from healthy donors were incubated with pure DNA of eight probiotic strains and with total bacterial DNA from human feces collected before and after probiotic ingestion. Cytokine production was analyzed in culture supernatants. Modification of human microflora after probiotic administration was proven by polymerase chain reaction analysis. Here we show that Bifidobacterium genomic DNA induced secretion of the antiinflammatory interleukin-10 by PBMC. Total bacterial DNA from feces collected after probiotic administration modulated the immune response by a decrease of interleukin-1l and an increase of interleukin-10. ß 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. Keywords: Bi dobacterium; Lactobacillus; Bacterial DNA; In ammatory bowel disease; Immune modulation 1. Introduction In ammatory bowel diseases (IBD) are characterized clinically by chronic in ammation in the intestine. The etiology of IBD remains unclear, even if human and experimental studies indicate that genetic host susceptibility, gut mucosal immune response and enteric bacteria may contribute to the pathogenesis of IBD [1]. The importance of bacteria in sustaining in ammation in IBD is further supported by the clinical experience that antibiotics reduce disease activity. Evidence exists that in patients with active IBD there is a breakdown of normal tolerance to the resident enteric bacteria ora which leads to an excessive * Correspondence author. Tel.: +39 (051) ; Fax: +39 (051) address: karenmanon@hotmail.com (K.M. Lammers). mucosal immune response against enteric bacteria [2]. Interleukin 10 (IL-10) is a cytokine of particular therapeutic interest in IBD since it plays a key role in the control of in ammatory responses to intestinal antigens and can restore tolerance of T cells to resident intestinal bacteria. Therapeutic bene t of IL-10 administration has been reported from experimental studies with IL-10-de cient mice [3] and in clinical trials with IBD patients [4] albeit that the clinical usefulness of IL-10 is limited for technical reasons related to the organ-speci c delivery [5]. Thus, a therapeutic approach based on IL-10 which overcomes these limitations would provide great perspectives. The important role of bacteria in the pathogenesis of IBD has suggested the possibility of preventing or treating these disorders by manipulating the intestinal micro ora with probiotic treatment. Members of the genera Lactobacillus and Bi dobacterium are amongst the most common microorganisms in the human gastrointestinal tract. Evidence exists that these bacteria exert health-promoting activity because they play an important role in the control of / 03 / $22.00 ß 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved. doi: /s (03)
2 166 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^172 the intestinal micro ora and in maintenance of its normal state [6]. Because of their bene cial properties Lactobacillus and Bi dobacterium strains are commonly used in dairy and pharmaceutical probiotic preparations. VSL#3 (VSL Pharmaceuticals, Ft. Lauderdale, FL, USA) contains 450 billion per sachet of a viable lyophilized bacterial mixture, including three strains of bi dobacteria (Bi dobacterium longum, Bi dobacterium breve, Bi dobacterium infantis), four strains of lactobacilli (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus plantarum) and one strain of Streptococcus salivarius subsp. thermophilus. In recent clinical studies, its e cacy was shown as maintenance treatment and prophylactic therapy in patients with IBD [7,8]. In addition, Ulisse et al. [9] showed an increased tissue level of IL-10 in pouch patients treated with this probiotic therapy. The therapeutic bene t of VSL#3 was also shown by experimental studies in IL-10 knock-out mice [10,11]. Madsen et al. [11] found that an unknown, soluble factor secreted by the bacteria of this probiotic preparation enhanced epithelial barrier function and resistance to pathogenic bacterial invasion in T84 epithelial cells. In addition, sonicates ^ containing soluble cytoplasmic fraction ^ of each Lactobacillus and Bi dobacterium VSL#3 strain did not induce IL-8 production in HT29 epithelial cells [12], but stimulated IL-10 secretion in peripheral blood mononuclear cells (PBMC) (U. Helwig, personal communication). In the past few years, immune e ects of unmethylated DNA sequences (CpG motifs), predominantly present in bacteria, have been described [13]. Considering the high GC content of Bi dobacterium and ^ to a lesser extent ^ Lactobacillus chromosomal DNA, we decided to examine the e ect of VSL#3 bacteria DNA on IL-1L, IL-6 and IL-10 secretion and to evaluate the response induced by total bacterial DNA isolated from feces of healthy subjects before and after 2 weeks of VSL#3 treatment. 2. Materials and methods 2.1. Bacterial strains and culture conditions The VSL#3 bacterial strains used in this study are the following: B. infantis BI07, B. breve BBSF, B. longum BL04, L. acidophilus LA14, L. delbrueckii subsp. bulgaricus LB31, L. casei LC10, L. plantarum LPT and S. salivarius subsp. thermophilus TA061, designated S. thermophilus throughout this paper. Bi dobacterium and Lactobacillus strains were grown anaerobically (Anaerobic System, Model 2028, Forma Scienti c, Marietta, OH, USA) in MRS medium (Difco, Detroit, MI, USA) supplemented with 0.05% L-cysteine, at 37 C. S. thermophilus was cultured anaerobically in M17 medium (Difco) at 37 C. Enumeration of probiotic bacteria in fecal samples was carried out as previously reported [14]. Counting of the probiotic bacterial groups was performed by spreading dilutions onto plates containing the following selective agar media: LAMVAB [15] for Lactobacillus, RB [16] for Bi dobacterium and ST [17] slightly modi ed by adding bromocresol purple (30 mg l 31 ), bromocresol green (100 mg l 31 ) and nalidixic acid (30 mg l 31 ) for S. thermophilus. Plates were anaerobically incubated at 37 C for 24^ 48 h. Bacterial concentrations were expressed as CFU g 31 dry feces. Speci c identi cation of VSL#3 B. infantis and B. breve strains was performed by polymerase chain reaction (PCR)-mediated ampli cation using the strain-speci c primers and experimental conditions previously described [14]. Quanti cation was carried out by direct ampli cation of 30^50 colonies randomly selected from the highest dilution plates of RB medium. The ratio between the number of colonies which gave positive amplicons with the strain-speci c primers and the total number of colonies analyzed by PCR was calculated, and successively related to the total number of colonies grown on the highest dilution plate DNA preparation Isolation of genomic DNA from pure cultures of the probiotic bacteria was performed as previously described [18]. In order to obtain complete cell disruption, the method was slightly modi ed by prolonging the enzymatic lysis from 1 to 3 h and grinding with glass beads (150^212 Wm, Sigma, St. Louis, MO, USA). Puri cation of total bacterial DNA from feces of two healthy donors, before (t 0 ) and after 2 weeks of probiotic ingestion (t 1 ), was performed using the QIAamp DNA stool kit (Qiagen, Milan, Italy). Concentration and purity of all DNA preparations were determined by measuring OD 260 absorbance and OD 260=280 ratio, respectively. Only DNAs with an OD 260=280 ratio s 1.8 were used. DNAs were also assayed for lipopolysaccharide (LPS) content using the Limulus amebocyte assay (QCL-1000, BioWhittaker, Walkersville, MD, USA). LPS content was less than 0.01 U endotoxin Wg 31 DNA Cell preparation and cell culture For each group of experiments, PBMC were isolated from peripheral blood of four healthy volunteers by density gradient centrifugation (1.077 g ml 31 ) (Lymphoprep, Nycomed Pharma, Oslo, Norway). Cells were resuspended in RPMI 1640 culture medium (Life Technologies, Paisley, UK) supplemented with 10% (v/v) heat-inactivated (56 C, 1 h) fetal bovine serum, gentamicin (50 Wg ml 31 ) (Sigma), penicillin^streptomycin (1%) and sodium pyruvate solution (0.23 mmol l 31 ) (Sigma) (complete medium). All compounds were purchased endotoxin tested. Cells were cultured in complete medium in a concentration of 1U10 6 cells ml 31 in 96-well plates (Nunc, Roskilde, Denmark) in
3 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^ a5%co 2 -humidi ed incubator at 37 C. All experiments were performed in duplicate Stimulation experiments Genomic DNAs from the probiotic strains were applied to PBMC at the following concentrations: 3, 6.25, 12.5, 25, 50, and 70 Wg ml 31 for 24 h. For kinetics, genomic DNA of two strains, L. casei and B. breve, was applied at a concentration of 20 Wg ml 31 over a period of 24, 48 and 72 h. Total bacterial genomic DNAs, isolated from feces at times t 0 and t 1, were applied to PBMC from three donors for 24 h. As a positive control, LPS (Sigma) at a concentration of 20 ng ml 31 was used. As a negative control, methylated DNA from sh sperm (Roche, Italy) was applied at the same concentrations used for bacterial DNA. At the indicated time points, supernatants were harvested for cytokine measurement, centrifuged and stored at 320 C until assay Enzyme-linked immunosorbent assay (ELISA) Culture supernatants were analyzed for IL-1L, IL-6 and IL-10 with commercially available anti-human monoclonal capture antibodies to IL-1L (MAB601) (RpD Systems, Abingdon, UK), IL-6 (18871D) and IL-10 (18551A) (Pharmingen, San Diego, CA, USA), and speci c biotinylated anti-human monoclonal detection antibodies to IL-1L (BAF201) (RpD systems), IL-6 (18882D) and IL-10 (18562D) (Pharmingen). o-phenylenediamine bu - er/h 2 O 2 (Sigma, Steinheim, Germany) was used as a substrate. Extravidin-peroxidase (Sigma) was applied at a concentration of 1:1000. Human recombinant IL-1L (201-LB-005) (RpD systems), human recombinant IL-6 (1966T) and IL-10 (19701V) (Pharmingen) were used as standards. The optical density values of the samples were read at 490 nm on an ELISA plate reader. The detection limit of the assay was 15.7 pg ml 31 for IL-1L and 31 pg ml 31 for IL-6 and IL Statistical analysis Experimental data are expressed as mean þ S.E.M. The statistical signi cance of di erences in mean values was determined with Student s t-test. Di erences were considered to be signi cant at P Results 3.1. Probiotic bacterial DNA elicits IL-1, IL-6 and IL-10production We investigated the implication of pure genomic DNAs from VSL#3 Bi dobacterium, Lactobacillus and S. thermophilus strains in the release of the cytokines IL-1L, IL-6 Fig. 1. PBMC from four healthy donors were cultured with 70 Wg ml 31 of each genomic DNA extracted from VSL#3 bacteria. IL-1L, IL-6 and IL-10 production was measured in supernatants. The cytokine response to bacterial DNAs was compared to that obtained with LPS (20 ng ml 31 ): *P , **P and IL-10. The rst encouraging results were obtained by challenging PBMC from healthy human subjects with 70 Wg ml 31 of bacterial DNA (Fig. 1). This dose was chosen accordingly to previous experimental results which established 50^100 Wg ml 31 as the maximal stimulatory dose range of Escherichia coli DNA [19]. To avoid stimulatory e ects due to contamination of bacterial proteins or LPSs, all DNA preparations used in the experiments had purity values (OD 260=280 s 1.8) and LPS contents ( U endotoxin Wg 31 DNA) previously demonstrated
4 168 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^172 to be inactive in immune stimulation [20]. Fish sperm DNA did not have stimulatory e ects on PBMC (data not shown). Genomic DNA induced strain-speci c immune e ects: by comparison with LPS, genomic DNAs of VSL#3 B. infantis, S. thermophilus, L. plantarum and L. bulgaricus stimulated a pronounced IL-1L secretion, whereas B. longum, L. acidophilus and L. casei DNAs induced a signi cantly lower IL-1L production. DNAs of B. breve, B. infantis and S. thermophilus elicited IL-6 levels comparable to that obtained by LPS, while genomic DNAs of B. longum and Lactobacillus strains induced signi cantly lower IL-6 concentrations. Interestingly, DNA isolated from B. breve, B. infantis and S. thermophilus stimulated high secretion of IL-10 which exceeded the LPS-induced IL-10 level up to three-fold. Subsequently, genomic DNAs of L. casei and B. breve were applied to PBMC at a concentration of 20 Wg ml 31 for 24, 48 and 72 h (Fig. 2). The DNAs of these strains were selected as representatives for the three Bi dobacterium and four Lactobacillus strains present in the VSL#3 mixture. The magnitude of IL-1L, IL-6 and IL-10 secretion reached maximal levels after 24 h of stimulation and then remained constant. Genomic DNA of B. breve was con rmed to be a more potent inducer of interleukins than L. casei DNA and was responsible for the highest IL-10 release Dose-dependent secretion of interleukins by bacterial DNA Fig. 2. PBMC from four healthy donors were incubated with 20 Wg ml 31 of genomic DNA of L. casei (closed squares) and B. breve (open squares) for 72 h. As controls medium (open circles) and LPS (20 ng ml 31 ) (closed circles) were used. Production of cytokines, assayed at intervals of 24 h, was compared to that induced by LPS: *P , **P Genomic DNA of each VSL#3 strain was then applied to the PBMC culture system at di erent concentrations, ranging from 3 to 70 Wg ml 31, to determine which dose induced the maximum cytokine secretion (Fig. 3). This dose interval was chosen on the basis of previously described experimental results showing that cytokine production by immune cells could be detected after application of at least 3 Wg ml 31 E. coli DNA, and optimal stimulation required a bacterial DNA concentration s 50 Wg ml 31 [19]. Two di erent patterns of cytokine response could be clearly distinguished: genomic DNAs of B. longum, S. thermophilus and Lactobacillus strains induced the highest levels of IL-1L at a concentration of 3 Wg ml 31, and lower stationary levels when applied at the concentration range of 6.25^70 Wg ml 31. In contrast, B. breve and B. infantis genomic DNAs showed a dose-dependent enhancement of IL-1L, reaching a plateau at concentrations of 12.5 Wg ml 31. It is noteworthy that genomic DNAs of L. acidophilus, L. casei and S. thermophilus induced signi cantly lower levels of IL-1L than did DNAs of the other strains. The IL-10 production pattern was similar to that of IL-1 showing the highest values after challenge with 3 Wg ml 31 of Lactobacillus strains, B. longum and S. thermophilus genomic DNAs, and lower stationary levels at the other doses applied. Genomic DNAs of B. breve and B. infantis induced a dose-dependent IL-10 secretion, reaching a plateau at a concentration of 12.5 Wg ml 31.In comparison with the other genomic DNAs, B. breve and B. infantis DNAs appeared to be the most potent IL-10 inducers, provoking a three-fold higher IL-10 secretion. Furthermore, IL-10 production stimulated by DNAs of these two strains exceeded IL-1L production over the whole dose range. Incubation with L. casei and S. thermophilus DNAs showed a weaker but analogous response. Conversely, B. longum and L. acidophilus DNAs induced signi cantly higher levels of IL-10 than IL-1L only at the concentration of 3 Wg ml 31. Challenge with genomic
5 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^ Fig. 3. PBMC from four healthy volunteers were challenged with di erent doses (3^70 Wg ml 31 ) of bacterial DNAs. IL-10 (closed circles) and IL-1L (open circles) secretion was determined after 24 h of incubation. IL-1L and IL-10 values obtained at each dose were compared: *P , **P
6 170 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^172 of total bacterial DNA extracted from feces at time t 0 and t 1 (Fig. 4). Fecal concentrations of lactobacilli, bi dobacteria and S. thermophilus, determined by culture techniques, showed an increase up to 3 logs after the probiotic treatment. At time t 0, bi dobacterial titer was 2.5U10 7 CFU g 31 and increased to 4U10 9 CFU g 31 at time t 1. t 0 and t 1 counts of lactobacilli were 3U10 5 CFU g 31 and 1.1U10 6 CFU g 31, while for S. thermophilus values of 7U10 3 CFU g 31 and 8U10 6 CFU g 31 were found. The availability of strain-speci c primers for VSL#3 B. breve and B. infantis [14] allowed their PCR detection and quanti cation in the fecal samples. B. breve and B. infantis strains were detected only after probiotic treatment at concentrations of 3U10 8 CFU g 31 and 1U10 8 CFU g 31, respectively, demonstrating that the increased fecal concentration of Bi dobacterium is related to the presence of these exogenous strains. A pronounced di erence in the cytokine response was observed after stimulation with t 0 and t 1 total bacterial DNAs extracted from feces of the two volunteers treated with VSL#3. DNA isolated from feces before the probiotic administration induced higher levels of IL-1L than IL-10, while DNA from feces after probiotic treatment enhanced the IL-10 secretion but reduced the IL-1L secretion. IL-6 production was not altered. 4. Discussion Fig. 4. PBMC from three healthy donors were cultured with 5 Wg ml 31 of total bacterial DNA extracted from feces of a healthy subject before and after 2 weeks of VSL#3 treatment. IL-1L (open circles) and IL-10 (closed circles) production was determined after 24 h of incubation. DNAs of L. plantarum and L. bulgaricus showed comparable levels of IL-1L and IL-10 at 3 Wg ml 31, but at higher doses (6.25^70 Wg ml 31 ) IL-1L exceeded signi cantly IL-10. The strain-related patterns, previously described, were also shown for IL-6. DNAs of B. breve and B. infantis induced in a dose-dependent way, and the other DNAs elicited the highest production at the lowest concentration (data not shown) Stimulatory e ects of fecal bacterial DNA on interleukin production Two healthy volunteers ingested for 2 weeks two sachets daily of VSL#3 (equivalent to 900 billion viable microorganisms), and feces were collected before (t 0 ) and after the probiotic administration (t 1 ). PBMC from three donors were challenged with a concentration of 5 Wg ml 31 The gut represents a complex ecosystem in which the intestinal micro ora and the host interact in order to maintain an immunologically balanced intestinal in ammatory response ( physiologic in ammation ). Several clinical and experimental studies indicate that the gut in ammation may be associated with an imbalance in intestinal micro ora, with a relative predominance of aggressive bacteria and an insu cient concentration of protective species. A recent therapeutic strategy in IBD involves manipulation of the local microenvironment by oral administration of probiotic bacteria, in order to restore the microbial balance [21]. The encouraging clinical results in IBD patients treated with the probiotic preparation VSL#3 have prompted us to elucidate the interaction between intestinal mucosa and microorganisms. Of particular interest are the results concerning the ability of VSL#3 probiotic bacteria to increase signi cantly the pouch tissue level of IL-10, and to reduce the proin ammatory cytokine levels [9]. Furthermore, a recent study demonstrated that the protective e ect of probiotic bacteria could be mediated by release of a soluble factor(s) that alters epithelial permeability and protects against pathogenic bacterial invasion [11]. These data raise the question whether this soluble proteinaceous factor or another di erent cytoplasmic bacterial component(s), such as DNA, could be involved in cytokine induction and modulation. Actually, substantial evidence exists that bacterial CpG motifs in-
7 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^ duce the immune response against challenge with a wide variety of pathogens and have therapeutic activity in murine models [22] and in human clinical trials [23]. In this perspective, we rst investigated the implication of pure genomic DNAs from VSL#3 Bi dobacterium, Lactobacillus and S. thermophilus strains in the release of the cytokines IL-1L, IL-6 and IL-10 using a human culture model. The results show that bacterial genomic DNA induces a remarkable strain-speci c immune response. A second series of experiments was designed to study whether the bene cial immune e ects observed during the VSL#3 treatment could be partly due to changes of the total bacterial DNA released by a modi ed micro ora. In this respect, bacterial DNA extracted from feces of healthy subjects collected before and after the probiotic administration was applied to the PBMC culture model. We consider this approach more appropriate to mimic the in vivo situation than investigating the stimulatory capacity of the DNA recovered from the VSL#3 mixture, as the intestinal colonization of exogenous bacteria is not strictly related to their concentrations in the pharmaceutical formulation but strain- and host-dependent. Interestingly, these experiments showed a diverse IL-1L and IL-10 cytokine production after stimulation with bacterial DNA isolated from feces before and after probiotic treatment. Bacterial DNA from micro ora before probiotic ingestion induced higher IL-1L than IL-10 secretion, contrarily, total bacterial DNA from a probiotics-enriched micro ora led to higher production of IL-10 than IL-1L. Our data suggest that genomic DNA released by exogenous bi dobacteria could provide a stimulus for mucosal IL-10 production. Taking into account that the manufacturing process and the gastroenteric passage a ect the bacterial viability, the results obtained in this study may indicate a potential therapeutic e ect of genomic DNA released by the dead bacteria ingested during the probiotic administration. Several articles describe di erent cytokine responses to CpG motifs present in bacterial DNA, some of these motifs exerting a more pronounced immunomodulatory e ect than others [13]. It would be interesting to know whether the strain-speci c cytokine release demonstrated in this study is related to the genomic sequence of each strain. However, the genome sequences of the VSL#3 probiotic strains have not yet been characterized and thus it is not possible to predict the redundancy of the di erent CpG motifs. At present, the only useful information available is the GC content. The high GC percentage reported in the literature for the Bi dobacterium species present in VSL#3 (58^61%) strongly suggests that the DNA composition may account for the cytokine response, and in particular that a high GC content favors IL-10 secretion. To our knowledge this is the rst report to show the immunomodulatory e ects of genomic DNA of probiotic bacteria. The observed di erences in kinetics and magnitude of IL-1L and IL-10 release in response to bacterial DNAs provide interesting information about the in uence of gut micro ora and/or bacterial components on the intestinal mucosal immune response. Acknowledgements K.M.L. is supported by a grant from the Fondazione del Monte di Bologna e Ravenna. References [1] Shanahan, F. (2002) Crohn s disease. Lancet 359, 62^69. [2] Duchmann, R., Kaiser, I. and Hermann, E. et al. (1995) Tolerance exists towards resident intestinal ora but is broken in active in ammatory bowel disease (IBD). Clin. Exp. Immunol. 102, 448^455. [3] Steidler, L., Hans, W. and Schotte, L. et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin 10. Science 289, 1352^1354. [4] Van Deventer, S.J., Elson, C.O. and Fedorak, R.N. (1997) Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn s disease. Gastroenterology 113, 383^389. [5] Shanahan, F. (2000) Therapeutic manipulation of gut ora. Science 289, 1311^1312. [6] Dunne, C., Murphy, L. and Flynn, S. et al. (1999) Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 76, 279^292. [7] Gionchetti, P., Rizzello, F. and Venturi, A. et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind placebo-controlled trial. Gastroenterology 119, 305^309. [8] Gionchetti, P., Rizzello, F. and Helwig, U. et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebocontrolled trial. Gastroenterology 124(5), 1202^1209. [9] Ulisse, S., Gionchetti, P. and D Alo, S. et al. (2001) Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: e ects of probiotic treatment. Am. J. Gastroenterol. 96, 2691^2699. [10] Madsen, K.L., Doyle, J.S. and Jewell, L.D. et al. (1999) Lactobacillus species prevents colitis in interleukin 10 gene-de cient mice. Gastroenterology 116, 1107^1114. [11] Madsen, K.L., Cornish, A. and Soper, P. et al. (2001) Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121, 580^591. [12] Lammers, K.M., Helwig, U. and Swennen, E. et al. (2002) E ect of probiotic strains on interleukin 8 production by HT29/19A cells. Am. J. Gastroenterol. 97, 1182^1186. [13] Krieg, A.M. (2002) CpG motifs in bacterial DNA and their immune e ects. Annu. Rev. Immunol. 20, 709^760. [14] Brigidi, P., Vitali, B. and Swennen, E. et al. (2000) Speci c detection of Bi dobacterium strains in a pharmaceutical probiotic product and in human feces by polymerase chain reaction. Syst. Appl. Microbiol. 23, 391^399. [15] Hartemink, R., Domenech, V.R. and Rombouts, F.M. (1997) LAM- VAB a new selective medium for the isolation of lactobacilli from feces. J. Microbiol. Methods 29, 77^84. [16] Hartemink, R., Kok, B.J. and Weenk, G.H. et al. (1996) Ra nose- Bi dobacterium (RB) agar, a new selective medium for bi dobacteria. J. Microbiol. Methods 27, 33^43. [17] Dave, R.I. and Shah, N.P. (1996) Evaluation of media for selective enumeration of Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, and bi dobacteria. J. Dairy Sci. 76, 1529^1536.
8 172 K.M. Lammers et al. / FEMS Immunology and Medical Microbiology 38 (2003) 165^172 [18] Alander, M., Satokari, R. and Korpela, R. et al. (1999) Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl. Environ. Microbiol. 65, 351^354. [19] Krieg, A.M., Yi, A.K. and Matson, S. et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546^549. [20] Gilkeson, G.S., Conover, J. and Halpern, M. et al. (1998) E ects of bacterial DNA on cytokine production by (NZB/NZW)F 1 mice. J. Immunol. 161, 3890^3895. [21] Campieri, M. and Gionchetti, P. (1999) Probiotics in in ammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 116, 1246^1249. [22] Rachmilewitz, D., Karmeli, F. and Takabayashi, K. et al. (2002) Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122, 1428^1441. [23] Agrawal, S. and Kandimalla, E.R. (2002) Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 8, 114^126.
השפעת חיידקים פרוביוטיים
השפעת חיידקים פרוביוטיים החיים בחלל )המעי(... על רון שאול יחידת גסטרו ילדים מרכז רפואי רמב"ם Introduction The intestinal microflora primarily in the large bowel consists mostly on benign bacterial species
More informationPROBIOTICS NEGATIVE ASPECTS
PROBIOTICS NEGATIVE ASPECTS Dr Ismail Moola Department of Medical Gastroenterology CMJAH University of Witwatersrand Putative Benefits of Probiotics Modulate Immune Intestinal Function Increase secretory
More informationFormulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.
Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01
More informationStudy summaries L. casei 431
This binder provides you with summaries of selected publications on Lactobacillus paracasei subsp. paracasei L. casei 431. The publications are clinical studies performed in humans documenting the effects
More informationSUPER PROBIO OR... 1 capsule! 20 BILLION. 40 pots WORLDWIDE BACTERIA PER CAPSULE PRACTITIONER STRENGTH
WORLDWIDE HEALTH CENTER Natural Health Products & Remedies Important note: This product fact sheet is for professional use and contains guideline information only. A direct copy of the information contained
More informationHMP is lead by NIH but is an International Consortium.
Human Microbiome The Human Microbiome Project was one of the spin offs of the Human Genome Project. The HMP project started in 2007 with the overall goal of Characterizing the Human Microbiome and determine
More informationEFFECTS OF ALETA IN PROMOTING THE GROWTH OF PROBIOTIC BACTERIA: IN VITRO STUDY
2 Senoko Drive 758 200 Singapore tel: +65.6755.633 www.kemin.com EFFECTS OF ALETA IN PROMOTING THE GROWTH OF PROBIOTIC BACTERIA: IN VITRO STUDY Lakshmibai Vasanthakumari Bindhu. Ph.D Abstract: It is well
More informationSurvival of new probiotic strains with anti-inflammatory & anti-obesity effects used in non-fat yogurt and low-fat Cheddar cheese making
Survival of new probiotic strains with anti-inflammatory & anti-obesity effects used in non-fat yogurt and low-fat Cheddar cheese making Veronique Demers-Mathieu, Ph.D. Department of Microbiology & Medicine
More informationAlimentary Pharmacology and Therapeutics SUMMARY
Alimentary Pharmacology and Therapeutics Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy a randomized, doubleblind, cross-over, placebo-controlled
More informationUnderstanding probiotics and health
Understanding probiotics and health Gemma Laws MSc Student Microbiology and Immunology Department The gut microbiota The name given to the total microbial population living in our intestine Bacteria, fungi,
More informationESPEN Congress Vienna Networking with your microbiota Specific evidence-based indications. H. Lochs (Germany)
ESPEN Congress Vienna 2009 Networking with your microbiota Specific evidence-based indications H. Lochs (Germany) Probiotics Evidence based indications H. Lochs Medizinische Klinik mit Schwerpunkt Gastroenterologie,
More informationMycobacterium avium resists exposure to the acidic conditions of the stomach
FEMS Microbiology Letters 182 (2000) 45^49 www.fems-microbiology.org Mycobacterium avium resists exposure to the acidic conditions of the stomach Thomas Bodmer a;b, Elizabeth Miltner a, Luiz E. Bermudez
More informationIncreasing barrier function with multispecies probiotics
Increasing barrier function with multispecies probiotics Elsbeth Pekelharing, MSc Science Liaison We strive for the most effective microbiome management solutions with our evidence-based & indication-specific
More informationProbiotics for Primary Prevention of Clostridium difficile Infection
Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss
More informationMashhad University of Medical Sciences. Azita Ganji MD, MPH
Mashhad University of Medical Sciences Azita Ganji MD, MPH 30.2.95 CD Food sensitivity (NCGS, ) Food intolerance IBS Gluten translocate through the epithelial mucosa via increased tight junction (TJ)
More informationIssue 3, September usio
Issue 3, September 2014 usio 1 Lactobacillus casei strain Shirota Research Update IMPROVEMENT IN INTESTINAL HEALTH 1. A probiotic fermented milk drink containing Lactobacillus casei strain Shirota improves
More informationRole of Food Matrix for Probiotic Effects
Role of Food Matrix for Probiotic Effects W. Kneifel Department of Food Science and Technology BOKU University of Natural Resources and Life Sciences Vienna Hohenheim, 15 Oct.. 2010 wolfgang.kneifel@boku.ac.at
More information[Type text] [Type text] [Type text]
[Type text] [Type text] [Type text] ISSN : 0974-7435 Volume 10 Issue 24 BioTechnology 2014 An Indian Journal FULL PAPER BTAIJ, 10(24), 2014 [16486-16491] Evaluation of Lactobacillus rhamnosus viability
More informationThe role of gut microbiome in IBS
The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard
More informationGut Lung Axis Implication of the Gut Microbiota beyond its niche
Gut Lung Axis Implication of the Gut Microbiota beyond its niche Reema Subramanian PhD Candidate (4 th year) Supervisor: Prof. Margaret Ip Department of Microbiology, CUHK Joint Graduate Student Seminar
More informationProbiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town
Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town Outline Introduction: a brief overview Probiotics: Current guidelines Reviews and Meta-analyses IBD
More informationEscherichia coli Nissle 1917
Immunoregulation in Inflammatory Bowel Diseases New therapeutic approaches Probiotics Escherichia coli Nissle 1917 Andreas Sturm Medizinische Klinik m.s. Hepatologie, Gastroenterologie, Endokrinologie
More informationThe effect of probiotics on animal health: a focus on host s natural intestinal defenses
The effect of probiotics on animal health: a focus on host s natural intestinal defenses Guillaume Tabouret Animal Health Dept. Joint Unit 1225 Host Pathogens Interactions History of probiotics and definition
More informationGut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI
Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human
More informationGood adhesion properties of probiotics: a potential risk for bacteremia?
FEMS Immunology and Medical Microbiology 31 (2001) 35^39 www.fems-microbiology.org Good adhesion properties of probiotics: a potential risk for bacteremia? E e Apostolou a, Pirkka V. Kirjavainen a, Maija
More informationPROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT PROBIOTICS: WHAT ARE THEY, AND HOW DO THEY WORK? Karen Jensen, (Retired ND)
PROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT Karen Jensen, (Retired ND) Today many people are aware of the benefits of maintaining a healthy gut. As a result, probiotic use is becoming ever more popular.
More informationClinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut
Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,
More informationFaecalibacterium prausnitzii
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:
More informationT en to 20% of patients with ulcerative colitis still undergo
18 INFLAMMATORY BOWEL DISEASE Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis T Mimura, F Rizzello, U Helwig, G Poggioli, S Schreiber, I C
More informationin the Gastrointestinal and Reproductive Tracts of Quarter Horse Mares
Influence of Probiotics on Microflora in the Gastrointestinal and Reproductive Tracts of Quarter Horse Mares Katie Barnhart Research Advisors: Dr. Kimberly Cole and Dr. John Mark Reddish Department of
More informationCorrespondence to: Tiina Mattila-Sandholm, VTT, PO Box 1500, FIN VTT, Finland. Fax: ;
REVIEW ARTICLE Lactobacillus paracasei subsp. paracasei F19: Survival, Ecology and Safety in the Human Intestinal Tract A Survey of Feeding Studies within the PROBDEMO Project R. Crittenden 1, M. Saarela
More informationSIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS.
SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello Microbiota e IBS Cesare Cremon Policlinico S. Orsola Malpighi Azienda Ospedaliero - Universitaria di
More informationBest use of a probiotic supplement (Symprove TM )
UCL School of Pharmacy You ve got to be in it to win it Best use of a probiotic supplement (Symprove TM ) Professor Simon Gaisford s.gaisford@ucl.ac.uk @sgaisforducl Probiotics Probiotic market estimated
More informationResearch Article. The effects of hyaluronic acid on the morphological physiological differentiation of Lactobacillus
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2016, 8(7):368-372 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 The effects of hyaluronic acid on the morphological
More informationPROBIONA. PROBIOTICS with 5 bacterial strains. Suitable during and after the use of antibiotics to restore intestinal microflora.
PROBIONA Probiotic supplement for adults PROBIOTICS with 5 bacterial strains Suitable during and after the use of antibiotics to restore intestinal microflora. 2.850 billion cfu per capsule guaranteed
More information2/3/2011. Adhesion of Bifidobacterium lactis HN019 to human intestinal
PROBIOTICS LEARNING THE WHY AND WHEN PROBIOTICS DEFINITION live micro-organisms organisms that are beneficial to the host organism WHO: Live organisms which, when administered in adequate amounts, confer
More informationThe impact of the microbiome on brain and cognitive development
The Gut-Brain Axis The impact of the microbiome on brain and cognitive development Diane Stadler, PhD, RD Oregon Health & Sciences University, Portland, Oregon Lao-American Nutrition Institute With acknowledgements
More informationProphylaxis of Pouchitis Onset With Probiotic Therapy: A Double-Blind, Placebo-Controlled Trial
GASTROENTEROLOGY 2003;124:1202 1209 Prophylaxis of Pouchitis Onset With Probiotic Therapy: A Double-Blind, Placebo-Controlled Trial PAOLO GIONCHETTI,* FERNANDO RIZZELLO,* ULF HELWIG,* ALESSANDRO VENTURI,*
More informationLavanya Nutankalva,MD Consultant: Infectious Diseases
Lavanya Nutankalva,MD Consultant: Infectious Diseases Introduction The word Probiotic was derived from the Greek phrase meaning for life." was first coined in the 1960s by Lilly and Stillwell. Probiotics
More informationAssessment of increase in probiotic potential of Lactobacillus strains fortified with Aloe vera
Original Article International Journal of Life Sciences International Peer Reviewed Open Access Refereed Journal Int. J. of Life Sciences, 2019; 7 (1):102-106 ISSN:2320-7817(p) 2320-964X(o) Open Access
More informationNatural and Holistic Medicine Approach in Evaluation and Treatment of Vaginal and Urinary Tract Health
Natural and Holistic Medicine Approach in Evaluation and Treatment of Vaginal and Urinary Tract Health By Dr. Michael John Badanek, BS, DC, CNS, CTTP, DACBN, DCBCN, MSGR./CHEV While the gut has an estimated
More informationProbiotics: Implications for Pediatric Health
Probiotics: Implications for Pediatric Health PREFACE It is no longer questioned that the interplay between our genes, nutrition, and our environment hold the keys to growth, development, and health.
More informationBacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3.2 0.9-26.8 U/g 1.2 0.2-3.3 mg/g 2.2 1.3-8.6 micromol/g 1.1 1.3-23.7 mg/g 1.1 0.2-3.5 mg/g Rare 1.0 0.2-8.8 mg/g Rare 4.4 2.6-32.4 mg/g 64.6 >= 13.6 micromol/g Bacteriology
More informationHomeopathic Products. Evidence??
Homeopathic Products Principle of analogy or Law of Similars Small or infinitesimal doses (3X-30C) Avogadro s number=6x10 23 = ~23X Succussion and potentization (see http://www.boiron.com/en/htm/02_medi_hom
More informationNEERJA HAJELA, PhD Head Science Yakult Danone India Pvt. Ltd.
NEERJA HAJELA, PhD Head Science Yakult Danone India Pvt. Ltd. What we already know. Functional Foods - foods that provide a health benefit beyond the traditional nutrients it contains.. American Dietetics
More informationComplementary & Alternative Therapies in IBD
Complementary & Alternative Therapies in IBD Laurie Rosales, APRN-CNP OSU Wexner Medical Center Division of Gastroenterology, Hepatology and Nutrition Complementary & Alternative Probiotics Cannabis Fish
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(7):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 07 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.707.433
More informationProbiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate
doi:10.1111/j.1440-1746.2008.05723.x GASTROENTEROLOGY Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate Navalpur S Nanda Kumar, Ramadass Balamurugan,
More informationBringing Synbiotic Interventions in Cancer to Practice: from bench to bedside The UC Davis Foods for Health Institute
Bringing Synbiotic Interventions in Cancer to Practice: from bench to bedside The UC Davis Foods for Health Institute Jennifer T. Smilowitz, PhD Associate Director, Human Studies Research jensm@ucdavis.edu
More informationBiacid: A EU approved natural growth promoter for Broilers
Biacid is a blend of calcium salts of organic acids and essential oils. Through the optimal combination of calcium salts of organic acids and essential oils, it enhances broiler microflora within the gut
More informationReduction of Population Levels of Some Indigenous Bacteria by Lactobacilli in the Gastrointestinal Tract of Gnotobiotic Rats
Microbiol. Immunol. Vol. 21 (9), 495-503, 1977 Reduction of Population Levels of Some Indigenous Bacteria by Lactobacilli in the Gastrointestinal Tract of Gnotobiotic Rats Tsugio WATANABE, Masami MOROTOMI,
More informationProbiotics- basic definition
Haworth Press 2007 Probiotics Terms: Probiotic Probiotics are live microorganisms (bacteria or yeasts) which, when administered in adequate amounts, confer a health benefit on the host Prebiotic - nutritional
More informationPROBIOTIC RESEARCH REVIEW
Probiotics in the Prevention of Eczema: A Randomised Controlled Trial (Allen at al. 2014) The probiotic formula that is used in GENESTRA BRANDS HMF Baby B and HMF Baby F was found to safely and effectively
More informationProbiotic. Prebiotics:
Probiotic This product has been formulated using a blend of select prebiotics with a wide array of probiotics, designed to naturally strengthen the immune system. The organisms in this formula are synergistic
More informationWhat Are Probiotics? PROBIOTICS
PROBIOTICS What Are Probiotics? Probiotics are living, microscopic (very small) organisms that can help your gut health. Most often, probiotics are bacteria, but they may also be other organisms, such
More informationBeta Glucan Synbiotic Formula Brief
Beta Glucan Synbiotic Formula Brief The Philosophy Complex chronic diseases are a mounting problem worldwide with many factors giving rise to a pandemic concern. Pollution, life style choices, stress levels,
More informationThe ability of probiotic bacteria to bind to human intestinal mucus
FEMS Microbiology Letters 167 (1998) 185^189 The ability of probiotic bacteria to bind to human intestinal mucus Pirkka V. Kirjavainen a; *, Arthur C. Ouwehand a, Erika Isolauri b, Seppo J. Salminen a
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationREF/2014/10/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 16 Dec 2017 12:41:27 GMT) CTRI Number Last Modified On 16/04/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationPARK, MYEONG SOO 1,2, MIN JEONG KIM 3, AND GEUN EOG JI 1,3 Q
J. Microbiol. Biotechnol. (2007),G17(7), 1120 1126 Assessment of Lipopolysaccharide-binding Activity of Bifidobacterium and Its Relationship with Cell Surface Hydrophobicity, Autoaggregation, and Inhibition
More informationPROFESSIONAL FORMULATION. ProBiotic & ProBiotic Multi. Probiotics: A Common Sense Discussion
PROFESSIONAL FORMULATION ProBiotic & ProBiotic Multi ProBiotic (V-PB) 25 Billion C.F.U/gram 90 capsules per bottle Non-Dairy ProBiotic Multi (V-PBM) 15 Billion C.F.U./gram 45 capsules per bottle Non-Dairy
More informationBacteriology. Mycology. Genova Diagnostics SAMPLE REPORT. Rare. Rare. Negative. Brown. Negative *NG. Negative
Completed: November 2010 Genova Diagnostics eceived: October 2010 Collected: October 2010 oute Number:7 4.2 0.9-26.8 U/g 0.9 0.2-3.3 mg/g 0.8 1.3-8.6 micromol/g 42.7 1.3-23.7 mg/g 1.7 0.2-3.5 mg/g are
More informationof Shigella with Bifidobacteria
Bifidobacteria Microflora Vol. 5(1), 51-55, 1986 Interaction of Shigella with Bifidobacteria Noboru OKAMURA,1* Rintaro NAKAYA,1 Hajime YOKOTA,2 Nobuya YANAI2 and Takuji KAWASHIMA2 Department of Microbiology,
More informationInfluence of Different Prebiotics and Probiotics on Selective Intestinal Pathogens
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 657-663 http://www.ijcmas.com Original Research Article Influence of Different Prebiotics and Probiotics on Selective Intestinal Pathogens Anayata Sharma 1*
More informationTHE HEALTHY GUT FOR AGING WELL
THE HEALTHY GUT FOR AGING WELL Aging A focus on health and aging always produces the same statement Things just do not work as well when we are older The question is why? If we were a car replace the parts
More informationSlide 1 THE HEALTHY GUT FOR AGING WELL. Slide 2 Aging. Slide 3 Aging
Slide 1 THE HEALTHY GUT FOR AGING WELL Slide 2 Aging A focus on health and aging always produces the same statement Things just do not work as well when we are older The question is why? If we were a car
More informationMore than a gut feeling: How the microbiota improves health
More than a gut feeling: How the microbiota improves health Amanda Ramer-Tait, PhD Harold and Esther Edgerton Assistant Professor of Immunology and Microbiology Department of Food Science, University of
More informationProbiotics and Health
Probiotics and Health March 2015 TABLE OF CONTENTS EXECUTIVE SUMMARY... 2 BACKGROUND AND DEFINITIONS... 4 FUNCTIONAL GASTROINTESTIINAL DISORDERS... 5 Irritable bowel syndrome... 5 Constipation... 6 INFLAMMATORY
More informationParticipants. probiotic. /placebo)
Table S1. Demographic characteristics of trials included in the meta-analysis. Study Birth weight (mean±sd) Gestation (wk) Feeding patterns Participants (probiotic /placebo) Probiotic agents Dosage Duration
More informationTher-Biotic Complete. Broad-spectrum synergistic multispecies probiotic formula. Supporting essential intestinal microdiversity
Ther-Biotic Complete Broad-spectrum synergistic multispecies probiotic formula Supporting essential intestinal microdiversity Ther-Biotic Complete Broad-spectrum synergistic multispecies probiotic formula
More informationProbiotics : What we Know and Where we are Going Next
Probiotics : What we Know and Where we are Going Next Neerja Hajela, Ph.D. General Manager - Science and Regulatory Affairs Yakult Danone India Pvt. Ltd. Functional Food Market Probiotics an important
More informationHOW THE MICROBIOME AFFECTS OUR HEALTH
HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins
More informationProbiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017
Probiotics: Their Role in Medicine Today Viki Barr Pharm.D., BCPS AQ ID Assistant Professor, Pharmacy Practice Rosalind Franklin University of Medicine and Science Clinical Pharmacist, Infectious Diseases
More informationAzienda Ospedaliera S. Camillo Forlanini. Unità Operativa di Gastroenterologia. Moscow June Cosimo Prantera
/ Azienda Ospedaliera S. Camillo Forlanini Unità Operativa di Gastroenterologia Moscow June 2006 Cosimo Prantera ANTIBIOTICS AND BACTERIAL SPECIES Metronidazole Bacteroides - Clostridia Ciprofloxacin Escherichia
More informationINTRODUCING YOUR GUT BACTERIA
INTRODUCING YOUR GUT BACTERIA Microflora Intestinal flora 1.5 kg We would die with 5 years of birth if we did not have them as we would not develop a proper immune system 1000 species and 5000 strains
More informationEfficacy of Lactobacillus GG in maintaining remission of ulcerative colitis
Alimentary Pharmacology & Therapeutics Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis M.A.ZOCCO,L.ZILERIDALVERME,F.CREMONINI,A.C.PISCAGLIA,E.C.NISTA,M.CANDELLI, M. NOVI, D.
More informationProbiotics for Disease Prevention and Amelioration. Neerja Hajela, PhD Yakult Danone India Pvt. Ltd.
Probiotics for Disease Prevention and Amelioration Neerja Hajela, PhD Yakult Danone India Pvt. Ltd. Microbiology turns inwards Human Metagenome project and Meta Hit project reveals that the gut micro flora
More informationProbiotics. NOW Guide to Probiotics
Probiotics NOW Guide to Probiotics The Health Benefits of Probiotics Microorganisms for Health Did you know that you have trillions of microorganisms, including bacteria and yeast, living in and on your
More informationThe enteric microbiota: Implications for IBD. Eugene B. Chang, M.D. University of Chicago
The enteric microbiota: Implications for IBD Eugene B. Chang, M.D. University of Chicago On a per cell basis, humans are mostly prokaryote 100 90 80 70 60 50 40 30 20 10 0 EuK ProK The microbial flora
More informationExosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE
Exosomes as a Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Endocrine Nurse Practitioner Institute for Hormonal Balance Orlando, FL Medical Director Ward-Murray
More informationCorporate Collaborations 2015
Corporate Collaborations 2015 Franco Vicariotto, MD Dep.of vulvovaginal disease.hospital V.Buzzi University of Milan PROBIOTICAL S.P.A. Italy GUNA S.P.A. Italy MEDA ROTTAPHARM S.P.A. Italy PHARMASUISSE
More informationAUTOIMMUNITY AND THE GUT
AUTOIMMUNITY AND THE GUT Autoimmunity The Past The rationale - All about a malfunctioning immune system The immune system is overactive to the point of attacking the body Avoid anything that stimulates
More informationEmerging Probiotic Research: A Guide to the Use of Probiotics in Clinical Practice
Emerging Probiotic Research: A Guide to the Use of Probiotics in Clinical Practice Donald Brown, ND April 13, 2010 Probiotics WHO Definition: Live microorganisms, which when administered in adequate amounts,
More informationGUT MICROBIOME WHAT IS IT? WHY IS IT IMPORTANT FOR HUMAN HEALTH?
GUT MICROBIOME WHAT IS IT? WHY IS IT IMPORTANT FOR HUMAN HEALTH? Corrie Whisner, PhD School of Nutrition and Health Promotion Arizona State University Center for Research on Ingredient Safety Annual Meeting
More informationPROBIOTICS. The Ultimate Flora Difference
In the Refrigerator Section! PROBIOTICS High-Potency Daily, Critical Care and Targeted Probiotic Formulas to Improve Regularity, Strengthen Natural Defenses and Promote Overall Digestion * The ReNew Life
More informationFonterra Probiotics: From guts to glory
Fonterra Probiotics: From guts to glory James Dekker April 16, 2015 Host Institution Probiotic bacteria Live micro-organisms which, when administered in adequate amounts, confer a health benefit on the
More informationCancer preventive effects of lactic acid bacteria
TALAB Symposium 2007. 11. 9. National Taiwan Univ. Cancer preventive effects of lactic acid bacteria Hyong Joo Lee Seoul National University 1 Total deaths from cancer and heart disease J. Natl. Cancer
More informationProbiotics in Pediatric Health. AANP Annual Convention
Probiotics in Pediatric Health AANP Annual Convention Don Brown, ND July 12, 2017 Human Microbiome Richness and Metabolic Markers Human gut microbial composition was studied in 292 Danish adults Individuals
More informationThe role of antibiotics and probiotics in pouchitis
INVITED REVIEW Annals of Gastroenterology (2012) 25, 1-6 The role of antibiotics and probiotics in pouchitis Paolo Gionchetti a, Andrea Calafiore a, Donatella Riso a, Giuseppina Liguori a, Carlo Calabrese
More informationFecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report
Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Qiurong Li Institute of General Surgery, Jinling Hospital Nanjing Univeristy Gut Microbiota 100 trillion cells 10-fold of
More informationQ What are Probiotics?
Q What are Probiotics? The word PROBIOTIC was originated from Latin and means For Life. Probiotics are good bacteria usually found in food products or supplements which play very important roles in regulating
More informationPATHOGENICITY OF MICROORGANISMS
PATHOGENICITY OF MICROORGANISMS Some microorganisms are : 1- Harmless microorganism, as normal flora 2- Harmfull microorganism, as pathogenic. A pathogenic microorganism is defined as one that causes or
More informationModulation of abdominal pain by probiotics. Anna Lyra, PhD DuPont Nutrition & Health
Modulation of abdominal pain by probiotics Anna Lyra, PhD DuPont Nutrition & Health Functional gastrointestinal (GI) wellbeing Up to 70% suffer from functional GI symptoms - ¾ do not seek medical care
More informationManipulating the gut microbiome
Manipulating the gut microbiome William DePaolo, PhD Associate Professor Medicine Director Center for Microbiome Sciences & Therapeutics University of Washington Microbiota The actual bugs that reside
More informationProbiotics. Wide spectrum of important health benefits
Probiotics Part 1: What Are Probiotics? Probiotics are live microorganisms that inhabit the respiratory and gastrointestinal tracts and the skin. They are often referred to as friendly bacteria as they
More informationThe role of nutrition in optimum gastrointestinal health
The role of nutrition in optimum gastrointestinal health Kelly A. Tappenden, Ph.D., R.D., FASPEN Kraft Foods Human Nutrition Endowed Professor University Distinguished Teacher-Scholar University of Illinois
More informationTOP 10 LEAKY GUT SUPPLEMENTS
TOP 10 LEAKY GUT SUPPLEMENTS HEALING LEAKY GUT Leaky Gut Supplements Leaky gut syndrome is a condition where undigested proteins like gluten, toxins and microbes can pass into the bloodstream. Another
More informationCranberry juice consumption may reduce bio lms on uroepithelial cells: pilot study in spinal cord injured patients
(2001) 39, 26 ± 30 ã 2001 International Medical Society of Paraplegia All rights reserved 1362 ± 4393/01 $15.00 www.nature.com/sc Cranberry juice consumption may reduce bio lms on uroepithelial cells:
More informationBacteriology. Mycology. Patient: REDOX Biomedicine Co., Ltd. Referring Laboratory Attn Alan Ou 5F, No. 369, Song Jiang Road Taipei, Taiwan
ex: MN: Completed: eptember 23, 2011 eceived: eptember 15, 2011 Collected: eptember 14, 2011 EDOX Biomedicine Co., Ltd. eferring Laboratory Attn Alan Ou 5F, No. 369, ong Jiang oad Taipei, 10482 Taiwan
More informationDownloaded from pidsphil.org For personal use only. No other uses without permission.
ORIGINAL ARTICLE Paolo Gene A. Becina, MD* Gener T. Becina, MD* *National Children s Hospital Correspondence: Dr. Paolo Gene A. Becina Email: paolobecina@yahoo.com The authors declare that the data presented
More information